NKGen Biotech Appoints New Board Members to Boost Asia-Pacific Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 03 2025
0mins
Source: Globenewswire
- Board Restructuring: NKGen Korea completed a shareholder-approved name change on November 21, 2025, and appointed three new board members, Hanhan Xu, Xuan Zhang, and Dr. June H. Lee, for three-year terms to enhance strategic governance in the Asia-Pacific region.
- Leadership Enhancement: The new directors bring extensive experience, with Hanhan Xu as a former co-founder of Waterdrop Holdings, Xuan Zhang as a former financial director at Guazi.com, and Dr. June H. Lee as a former Chief Development Officer at MyoKardia, which will significantly support NKGen Korea's NK cell therapy development.
- Market Positioning: As a majority-owned subsidiary of NKGen, NKGen Korea focuses on developing advanced NK cell therapies, and the new board members are expected to drive its commercialization efforts in the Asia-Pacific market, aiding the company's recovery from rehabilitation and accelerating growth.
- Future Outlook: NKGen CEO Paul Y. Song stated that the establishment of the new board will inject fresh energy into NKGen Korea's leadership, with expectations to accelerate the development of NK cell therapies and lay the groundwork for future commercialization.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
